Xeljanz Lawsuit
If you or a loved one has been affected by the Xeljanz medication, you may be entitled to compensation. You may be entitled to significant financial compensation. Contact the Showard Law Firm to learn about your legal options. We offer free initial case reviews. If you have suffered any of the side effects listed above, you may have a strong case.
Xeljanz causes cancer
The risk of developing cancer is one of the biggest concerns for Xeljanz users, according to a study by Pfizer. The drug is associated with an increased risk of developing lung, prostate, and lymphoma cancers, according to the study. However, the FDA has not updated its labeling with information on the drug’s relationship with cancer.
Xeljanz inhibits a group of enzymes in the immune system, known as JAKs. These enzymes contribute to inflammation. By inhibiting them, Xeljanz reduces the immune response. It is used for rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis.
In February 2021, the FDA issued a new safety alert regarding Xeljanz, warning that the drug can increase the risk of developing cancer and serious cardiovascular events. While the risks were not severe, the new warnings could affect patients taking lower doses of the drug.
Xeljanz causes heart problems
Xeljanz is a controversial anti-inflammatory drug that is approved for the treatment of ulcerative colitis. However, recent reports have linked the drug with heart problems and cancer. The FDA issued a safety communication warning about the drug on Feb. 4, 2011, alerting healthcare professionals and patients to new clinical trial results. The findings have raised concerns that patients and healthcare professionals should be aware of potential risks, including the risk of cancer and heart problems.
The FDA issued a warning about Xeljanz’s possible link to pulmonary embolism, a potentially fatal condition caused by blood clots in the lungs. The warning applies to all Xeljanz indications and doses. A black box warning on the drug’s label will inform both doctors and patients of the risks.
While it’s rare, some people who take Xeljanz have experienced serious adverse reactions. These reactions can include swelling under the skin, mouth or tongue, or trouble breathing. If you experience these side effects, contact your healthcare provider right away.
Xeljanz causes pulmonary embolism
Some patients taking Xeljanz have developed a potentially life-threatening blood clotting disorder known as pulmonary embolism. Without proper treatment, pulmonary embolism can develop into a life-threatening condition, and as many as 50,000 people die from it each year. Thankfully, the company that makes the drug has taken action to protect its patients.
Although the FDA has yet to rule definitively whether or not Xeljanz causes pulmonary embolism, it has warned that patients should be closely monitored for the risk of PE. The manufacturer of Xeljanz has since made an update to the drug label to include a warning about the increased risk of pulmonary embolism. This warning has been cited in numerous Xeljanz lawsuits filed by victims who claim that the drug’s manufacturer failed to adequately warn patients about this risk.
In 2012, the FDA issued a statement acknowledging the risks associated with Xeljanz. The agency noted that this medicine increased the risk of pulmonary embolism and was associated with other cardiovascular problems. Furthermore, patients taking Xeljanz have a higher risk of developing diabetes mellitus and impaired glucose tolerance.
Xeljanz causes pulmonary thrombosis
Xeljanz is a drug that has been used in the treatment of ulcerative colitis and rheumatoid arthritis since 2012. It has been linked to serious side effects, including blood clots in the lungs. This condition can be life-threatening.
Although the exact cause of pulmonary thrombosis is still unknown, it is known that Xeljanz can increase the risk of developing blood clots in the lungs. These clots can travel to other parts of the body and cause life-threatening complications, such as pulmonary embolism and cardiac arrest. Patients who are taking the medication should immediately seek medical attention if they develop any symptoms of this condition.
Although the drug makers knew that Xeljanz caused pulmonary thrombosis, they failed to warn consumers about the risks. The company failed to warn consumers about the risks of high doses of the medication, and the lawsuits against Pfizer are expected to continue. Many Xeljanz lawsuits are pending, and many former users are filing these claims against the drug maker to seek compensation for their injuries.
